# US 2026/0183378 A1 · Methods for treating hpv-associated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0183378 A1
- Document ID: US20260183378A1
- Status: Published application
- Kind: A1
- Application number: 19/568,167
- Filed: 2026-03-16
- Published: 2026-07-02
- Earliest claimed: 2018-03-12
- Assignees: Stemcell Technologies Canada Inc.
- Applicants: Stemcell Technologies Canada Inc.
- Inventors: Scott LOUGHHEAD; LeeAnn TALARICO; Alfonso VICENTE-SUAREZ; Matt BOOTY; Howard BERNSTEIN; Katarina BLAGOVIC; Armon R. SHAREI; Kelan HLAVATY; Melissa MYINT
- Web page: https://patentgrep.com/patent/US20260183378A1

## CPC

- A61K 39/12: Viral antigens
- A61K 33/243: Platinum; Compounds thereof
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/13: B-cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61K 40/46: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- C07K 14/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/39: characterised by a specific adjuvant, e.g. cytokines or CpG
- A61K 2239/55: Lung
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and/or for modulating an immune response in an individual with an HPV-associated disease.

## Claims

### Claim 1

A method of preparing modified immune cells comprising an antigen intracellularly, or an antigen and an adjuvant intracellularly, the method comprising the steps of:
a) passing a cell suspension comprising an input immune cell through a cell-deforming constriction, wherein a diameter of the constriction is a function of a diameter of the input immune cell in the suspension, thereby causing perturbations of the input immune cell large enough for the antigen, or the antigen and the adjuvant to pass through to form a perturbed input immune cell; and
b) incubating the perturbed input immune cell with the antigen, or the antigen and the adjuvant for a sufficient time to allow the antigen, or the antigen and the adjuvant to enter the perturbed input immune cell; thereby generating the modified immune cells,
wherein the modified immune cells further comprise an agent that enhances the viability and/or function of the modified immune cells as compared to corresponding modified immune cells that does not comprise the agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antigen:
i) is a polypeptide antigen;
ii) is modified with a lipid;
iii) is a viral antigen;
iv) is derived from a cell lysate; or
v) is a single antigen or a mixture of antigens, and/or
wherein the adjuvant comprises CpG oligodeoxynucleotide (CpG ODN), interferon-α (IFN-α), stimulator of interferon genes (STING) agonists, retinoic acid-inducible gene I (RIG-I) agonists, polyinosinic:polycytidylic acid (poly I:C), or combinations thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein:
i) the diameter of the constriction is less than the diameter of the cell;
ii) the diameter of the constriction is about 20% to 99% of the diameter of the cell;
iii) the constriction is in a channel; and/or
iv) a deforming force is applied to the input immune cell as it passes through the constriction.

### Claim 4 (depends on 1)

The method of claim 1, wherein:
i) a concentration of the adjuvant incubated with the perturbed input immune cell is between about 0.1 μM and about 1 mM;
ii) a concentration of the antigen incubated with the perturbed input immune cell is between about 0.1 μM and about 1 mM;
iii) a ratio of antigen to adjuvant incubated with the perturbed input immune cell is between about 10000:1 and about 1:10000; and/or
iv) a concentration of the modified immune cells ranges from about 10 to at least about 1012 cells/ml.

### Claim 5 (depends on 1)

The method of claim 1, wherein:
i) the agent is a compound that enhances endocytosis, a stabilizing agent or a co-factor;
ii) the agent is albumin; or
iii) the agent is glucose, ATP, potassium, glycerol, trehalose, D-sucrose, PEG 1500, L-arginine, L-glutamine, or EDTA.

### Claim 6 (depends on 1)

The method of claim 1, wherein the modified immune cells are further modified to increase expression of one or more of co-stimulatory molecules, and wherein the co-stimulatory molecule is B7-H2, B7-1, B7-2, CD70, LIGHT, HVEM, CD40, 4-1BBL, OX40L, TL1A, GITRL, CD30L, TIM4, SLAM, CD48, CD58, CD155, or CD112.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immune cell is a T cell, a B cell, a dendritic cell, a monocyte, a macrophage, a myeloid cell, a granulocyte, a neutrophil, a mast cell, a natural killer cell, an innate lymphoid cell, a basophil, a hematopoetic precursor cell, or a mixed cell population.

### Claim 8 (depends on 1)

The method of claim 1, wherein the immune cells are a plurality of PBMCs, or wherein the immune cells are T cells including one or more of helper T cells, cytotoxic T cells, memory T cells, CIK cells and natural killer T cells.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering the modified immune cell to an individual.

### Claim 10 (depends on 9)

The method of claim 9, wherein the modified immune cell is allogeneic or autologous to the individual.

### Claim 11 (depends on 9)

The method of claim 9, further comprising administering to the individual an adjuvant.

### Claim 12 (depends on 9)

The method of claim 9, wherein the modified immune cell is administered in combination with:
i) administration of an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is targeted to one or more of PD-1, PD-L1, CTLA-4, LAG3, TIM-3, TIGIT, VISTA, TIM1, B7-H4 (VTCN1) or BTLA; and/or
ii) administration of a chemotherapy, wherein the chemotherapy comprises a platinum based agent or cisplatin.

### Claim 13 (depends on 1)

The method of claim 1, wherein:
i) the modified immune cells comprising the antigen at a concentration of about 50 μM or lower lead to a higher antigen-specific response compared to modified immune cells comprising the antigen at a concentration greater than 50 μM; and/or
ii) the modified immune cells comprising the adjuvant at a concentration of about 200 μg/ml induce a higher antigen-specific response compared to modified immune cells comprising the adjuvant at a concentration of about 50 μg/ml or about 100 μg/ml.

### Claim 14 (depends on 2)

The method of claim 2, wherein the modified immune cells comprising the mixture of antigens lead to a higher antigen-specific response compared to modified immune cells prepared by incubating an input immune cell with the mixture of antigens.

### Claim 15 (depends on 1)

The method of claim 1, wherein the modified immune cells comprising the antigen and the adjuvant intracellularly lead to a greater activation of antigen-specific T cells compared to modified immune cells comprising the antigen intracellularly and not comprising the adjuvant intracellularly in combination with systemic administration of the adjuvant.

### Claim 16 (depends on 1)

The method of claim 1, wherein the modified immune cells comprising i) the antigen intracellularly and not comprising the adjuvant intracellularly, and systemic administration of an adjuvant; or ii) the antigen and the adjuvant intracellularly, lead to a higher reduction in tumor burden compared to systemic administration of the adjuvant.

### Claim 17 (depends on 1)

The method of claim 1, wherein the modified immune cells comprising the antigen and the adjuvant intracellularly in combination with systemic administration of a second adjuvant leads to a higher activation of antigen-specific T cells compared to the modified immune cells comprising the antigen and the adjuvant administered in combination with systemic administration of the adjuvant.

### Claim 18 (depends on 1)

The method of claim 1, wherein the modified immune cells comprising the antigen intracellularly administered in combination with a systemic adjuvant:
i) lead to higher activation of antigen-specific T cells; and/or
ii) induce a higher level of antigen-specific tumor infiltrating lymphocytes (TILs), compared to modified immune cells comprising the antigen alone.

### Claim 19 (depends on 1)

The method of claim 1, wherein the modified immune cells present the antigen directly.

### Claim 20 (depends on 1)

The method of claim 1, wherein the modified immune cells do not alter i) serum cytokine levels in vivo; and/or ii) cytokine levels in vitro compared to unmodified immune cells.
